Increased genitourinary fistula rate after bevacizumab in recurrent cervical cancer patients initially treated with definitive radiochemotherapy and image-guided adaptive brachytherapy

Background and purpose Patients with recurrent cervical cancer (RecCC) who received definitive radiochemotherapy including image-guided adaptive brachytherapy (IGABT) as primary treatment are currently treated in our institution with palliative intent by chemotherapy (CHT) combined with bevacizumab...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Strahlentherapie und Onkologie 2017-12, Vol.193 (12), p.1056-1065
Hauptverfasser:	Sturdza, Alina, Hofmann, Sandra, Kranawetter, Marlene, Polterauer, Stephan, Grimm, Christoph, Krainer, Michael, Kirisits, Christian, Pötter, Richard, Reinthaller, Alexander, Schwameis, Richard
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic Agents, Immunological - therapeutic use Austria - epidemiology Bevacizumab - therapeutic use Brachytherapy - utilization Cancer Cervical cancer Chemoradiotherapy - utilization Chemotherapy Combined Modality Therapy - utilization Digestive System Fistula - epidemiology Female Humans Immunotherapy Incidence Medicine Medicine & Public Health Middle Aged Monoclonal antibodies Neoplasm Recurrence, Local - epidemiology Neoplasm Recurrence, Local - therapy Oncology Original Original Article Patients Radiation therapy Radiotherapy Radiotherapy, Image-Guided - utilization Retrospective Studies Risk analysis Risk Factors Targeted cancer therapy Urinary Fistula - epidemiology Uterine Cervical Neoplasms - epidemiology Uterine Cervical Neoplasms - therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!